BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 26577528)

  • 21. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
    Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
    Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14).
    Wang R; Wang ZX; Yang JS; Pan X; De W; Chen LB
    Oncogene; 2011 Jun; 30(23):2644-58. PubMed ID: 21358675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC.
    Xie WB; Liang LH; Wu KG; Wang LX; He X; Song C; Wang YQ; Li YH
    Cell Physiol Biochem; 2018; 46(2):654-663. PubMed ID: 29617683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells.
    Chakraborty S; Mazumdar M; Mukherjee S; Bhattacharjee P; Adhikary A; Manna A; Chakraborty S; Khan P; Sen A; Das T
    FEBS Lett; 2014 Feb; 588(4):549-59. PubMed ID: 24444609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small RNA combination therapy for lung cancer.
    Xue W; Dahlman JE; Tammela T; Khan OF; Sood S; Dave A; Cai W; Chirino LM; Yang GR; Bronson R; Crowley DG; Sahay G; Schroeder A; Langer R; Anderson DG; Jacks T
    Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3553-61. PubMed ID: 25114235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer.
    Liu F; Wang X; Li J; Gu K; Lv L; Zhang S; Che D; Cao J; Jin S; Yu Y
    Cell Prolif; 2015 Oct; 48(5):582-92. PubMed ID: 26250586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S; Wang K; Huang X; Zhao Z; Zhao Z
    Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion.
    Wu X; Cheng YL; Matthen M; Yoon A; Schwartz GK; Bala S; Taylor AM; Momen-Heravi F
    J Exp Clin Cancer Res; 2021 Feb; 40(1):70. PubMed ID: 33596979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
    Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
    Front Immunol; 2018; 9():1613. PubMed ID: 30123214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-15a/16 enhances radiation sensitivity of non-small cell lung cancer cells by targeting the TLR1/NF-κB signaling pathway.
    Lan F; Yue X; Ren G; Li H; Ping L; Wang Y; Xia T
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):73-81. PubMed ID: 25442346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.
    Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C
    Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met.
    Wang LG; Ni Y; Su BH; Mu XR; Shen HC; Du JJ
    Int J Oncol; 2013 Mar; 42(3):957-62. PubMed ID: 23314612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
    Jiao P; Hou J; Yao M; Wu J; Ren G
    Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PAI-1/PIAS3/Stat3/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in Non-small cell lung cancer.
    Lin X; Lin BW; Chen XL; Zhang BL; Xiao XJ; Shi JS; Lin JD; Chen X
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1464-1470. PubMed ID: 28988111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma.
    Xiao P; Liu WL
    Int J Clin Exp Pathol; 2015; 8(9):10800-7. PubMed ID: 26617792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251.
    Luan S; Sun L; Huang F
    Arch Med Res; 2010 Feb; 41(2):67-74. PubMed ID: 20470934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.